# Kazuto Nishio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6355337/publications.pdf

Version: 2024-02-01

| 86 | 3,118 | 185998 | 168136 |
|---|---|---|---|
| papers | citations | 28 h-index | 53 g-index |

| 89 | 89 | 89 | 5368 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapyâ€induced colitis. Molecular Oncology, 2022, 16, 1493-1507. | 2.1 | 17 |
| 2 | Predictive value of EGFR mutation in nonâ€“smallâ€cell lung cancer patients treated with platinum doublet postoperative chemotherapy. Cancer Science, 2022, 113, 287-296. | 1.7 | 10 |
| 3 | Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naÃ¯ve advanced non-small-cell lung cancer. European Journal of Cancer, 2022, 161, 44-54. | 1.3 | 7 |
| 4 | Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period. Hepatology International, 2022, 16, 135-147. | 1.9 | 1 |
| 5 | A Randomized Phase II Study Comparing Nivolumab with Carboplatinâ€“Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research, 2022, 28, 893-902. | 3.2 | 35 |
| 6 | ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells. Cells, 2022, 11, 702. | 1.8 | 5 |
| 7 | RELAY+: Exploratory Study of Ramucirumab PlusÂGefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC. JTO Clinical and Research Reports, 2022, 3, 100303. | 0.6 | 1 |
| 8 | HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2022, 28, 390-403. | 3.2 | 34 |
| 9 | Performance of Idyllaâ„¢ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer. International Journal of Clinical Oncology, 2022, 27, 1180-1187. | 1.0 | 5 |
| 10 | Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Nonâ€“Small Cell Lung Cancers: Analysis of Five Cases. Clinical Lung Cancer, 2021, 22, e141-e145. | 1.1 | 5 |
| 11 | Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq1 1 0.784314 rgBT /Ove | 1.0 | 49 |
| 12 | Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. British Journal of Cancer, 2021, 124, 914-924. | 2.9 | 37 |
| 13 | Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANGâ€TR). Cancer Science, 2021, 112, 388-396. | 1.7 | 16 |
| 14 | Predicting osimertinibâ€treatment outcomes through EGFR mutantâ€fraction monitoring in the circulating tumor DNA of EGFR T790Mâ€positive patients with nonâ€small cell lung cancer (WJOG8815L). Molecular Oncology, 2021, 15, 126-137. | 2.1 | 12 |
| 15 | Molecular biomarker identification for esophageal adenocarcinoma using endoscopic brushing and magnified endoscopy. Esophagus, 2021, 18, 306-314. | 1.0 | 2 |
| 16 | A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).. Journal of Clinical Oncology, 2021, 39, 9037-9037. | 0.8 | 5 |
| 17 | Guidelines for clinical evaluation of antiâ€cancer drugs. Cancer Science, 2021, 112, 2563-2577. | 1.7 | 17 |
| 18 | Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma. Modern Pathology, 2021, 34, 2071-2079. | 2.9 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model. Cancers, 2021, 13, 3683. | 1.7 | 7 |
| 20 | High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib. JTO Clinical and Research Reports, 2021, 2, 100191. | 0.6 | 5 |
| 21 | Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA. Cancer Science, 2021, 112, 3911-3917. | 1.7 | 17 |
| 22 | Context-Specific Efficacy of Apalutamide Therapy in Preclinical Models of Pten-Deficient Prostate Cancer. Cancers, 2021, 13, 3975. | 1.7 | 4 |
| 23 | Genetic profile of adult Tâ€cell leukemia/lymphoma in Okinawa: Association with prognosis, ethnicity, and HTLVâ€1 strains. Cancer Science, 2021, 112, 1300-1309. | 1.7 | 14 |
| 24 | Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis. Frontiers in Oncology, 2021, 11, 763468. | 1.3 | 10 |
| 25 | METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society. Japanese Journal of Lung Cancer, 2021, 61, 361-370. | 0.0 | 3 |
| 26 | Decreased expression of Tâ€cellâ€associated immune markers predicts poor prognosis in patients with follicular lymphoma. Cancer Science, 2021, , . | 1.7 | 5 |
| 27 | Longitudinal monitoring of somatic genetic alterations in circulating cellâ€free DNA during treatment with epidermal growth factor receptorâ€“tyrosine kinase inhibitors. Cancer, 2020, 126, 219-227. | 2.0 | 20 |
| 28 | Impact of coexisting gene mutations in EGFR-mutated nonâ€“small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs. Lung Cancer, 2020, 139, 28-34. | 0.9 | 5 |
| 29 | Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. Gynecologic Oncology, 2020, 156, 415-422. | 0.6 | 28 |
| 30 | Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Lung Cancer, 2020, 148, 100-104. | 0.9 | 6 |
| 31 | Multiplex geneâ€panel testing for lung cancer patients. Pathology International, 2020, 70, 921-931. | 0.6 | 29 |
| 32 | Heterogeneity in congenital melanocytic nevi contributes to multicentric melanomagenesis. Journal of Dermatological Science, 2020, 100, 217-219. | 1.0 | 1 |
| 33 | Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib. Scientific Reports, 2020, 10, 691. | 1.6 | 8 |
| 34 | Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790Mâ€“positive nonâ€“small cell lung cancer: West Japan Oncology Group 8815L/LPS study. Cancer, 2020, 126, 1940-1948. | 2.0 | 18 |
| 35 | Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients. Cancer Science, 2019, 110, 3350-3357. | 1.7 | 8 |
| 36 | Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing. Scientific Reports, 2019, 9, 10426. | 1.6 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Successful long-term treatment of nonâ€“small cell lung cancer positive for RET rearrangement with pemetrexed . OncoTargets and Therapy, 2019, Volume 12, 5355-5358. | 1.0 | 1 |
| 38 | Performance of Oncomine Fusion Transcript kit for formalinâ€fixed, paraffinâ€embedded lung cancer specimens. Cancer Science, 2019, 110, 2044-2049. | 1.7 | 11 |
| 39 | Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. Lung Cancer, 2019, 132, 59-64. | 0.9 | 18 |
| 40 | Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA. Oncologist, 2019, 24, 1022-1026. | 1.9 | 16 |
| 41 | Impact of cytotoxic chemotherapy on PD-L1 expression in patients with nonâ€“small cell lung cancer negative for EGFR mutation and ALK fusion. Lung Cancer, 2019, 127, 59-65. | 0.9 | 36 |
| 42 | Mutational activation of the epidermal growth factor receptor downâ€regulates major histocompatibility complex class I expression via the extracellular signalâ€regulated kinase in nonâ€“small cell lung cancer. Cancer Science, 2019, 110, 52-60. | 1.7 | 31 |
| 43 | An HER3-targeting antibodyâ€“drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. Oncogene, 2019, 38, 1398-1409. | 2.6 | 69 |
| 44 | Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy. JCI Insight, 2019, 4, . | 2.3 | 26 |
| 45 | U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. Journal of Clinical Investigation, 2019, 130, 374-388. | 3.9 | 43 |
| 46 | Exploration of resistance mechanisms for epidermal growth factor receptorâ€tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and nextâ€generation sequencing. Cancer Science, 2018, 109, 3921-3933. | 1.7 | 27 |
| 47 | Clinical practice guidance for nextâ€generation sequencing in cancer diagnosis and treatment (Edition) Tj ETQq1 1 0.784314 rgBT /Ove | 1.7 | 38 |
| 48 | A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Breast, 2018, 40, 67-75. | 0.9 | 34 |
| 49 | A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutationâ€“Positive Nonsquamous Nonâ€“Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. Clinical Lung Cancer, 2017, 18, 719-723. | 1.1 | 13 |
| 50 | Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. Cancer Letters, 2017, 405, 22-28. | 3.2 | 17 |
| 51 | Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. International Journal of Oncology, 2017, 50, 2049-2058. | 1.4 | 15 |
| 52 | The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells. Oncotarget, 2017, 8, 70736-70751. | 0.8 | 26 |
| 53 | Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR) Tj ETQq1 1 0.784314 rgBT /Ove | 0.8 | 66 |
| 54 | HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer. Oncotarget, 2016, 7, 3453-3460. | 0.8 | 64 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Tumor volume determines the feasibility of cellâ€free DNA sequencing for mutation detection in nonâ€small cell lung cancer. Cancer Science, 2016, 107, 1660-1666. | 1.7 | 31 |
| 56 | <scp>FGFR</scp> gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer Science, 2016, 107, 1667-1676. | 1.7 | 31 |
| 57 | Randomized study of <scp>FOLFIRI</scp> plus either panitumumab or bevacizumab for wildâ€type <scp>KRAS</scp> colorectal cancerâ€<scp>WJOG</scp> 6210G. Cancer Science, 2016, 107, 1843-1850. | 1.7 | 60 |
| 58 | Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients. Scientific Reports, 2016, 6, 36458. | 1.6 | 75 |
| 59 | Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. Lung Cancer, 2016, 91, 36-40. | 0.9 | 38 |
| 60 | Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer. Oncotarget, 2016, 7, 15959-15976. | 0.8 | 20 |
| 61 | Randomized phase <scp>II</scp>/<scp>III</scp> clinical trial of elpamotide for patients with advanced pancreatic cancer: <scp>PEGASUS</scp>â€<scp>PC</scp> Study. Cancer Science, 2015, 106, 883-890. | 1.7 | 78 |
| 62 | Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Scientific Reports, 2015, 5, 14447. | 1.6 | 71 |
| 63 | Clinicopathological and genetic differences between lowâ€grade and highâ€grade colorectal mucinous adenocarcinomas. Cancer, 2015, 121, 4359-4368. | 2.0 | 16 |
| 64 | Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples. Oncotarget, 2015, 6, 30850-30858. | 0.8 | 72 |
| 65 | Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter. Oncology Letters, 2015, 9, 405-410. | 0.8 | 5 |
| 66 | Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer. SpringerPlus, 2015, 4, 7. | 1.2 | 9 |
| 67 | MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. Lung Cancer, 2015, 90, 590-597. | 0.9 | 32 |
| 68 | Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. Cancer Letters, 2015, 356, 819-827. | 3.2 | 75 |
| 69 | Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PLoS ONE, 2015, 10, e0121891. | 1.1 | 30 |
| 70 | Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib. Oncotarget, 2015, 6, 21636-21644. | 0.8 | 19 |
| 71 | Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1827-1831. | 0.5 | 7 |
| 72 | Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin. PLoS ONE, 2014, 9, e94772. | 1.1 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells. PLoS ONE, 2014, 9, e104372. | 1.1 | 25 |
| 74 | MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations. Molecular Cancer Therapeutics, 2014, 13, 3098-3106. | 1.9 | 16 |
| 75 | Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in aPTEN-deficient mouse model of prostate cancer. Carcinogenesis, 2014, 35, 2142-2153. | 1.3 | 23 |
| 76 | Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer. Lung Cancer, 2014, 83, 329-333. | 0.9 | 45 |
| 77 | Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer. Molecular Cancer, 2014, 13, 126. | 7.9 | 31 |
| 78 | LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both. Journal of Clinical Oncology, 2013, 31, 3335-3341. | 0.8 | 303 |
| 79 | Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation. Journal of Thoracic Oncology, 2012, 7, 1640-1644. | 0.5 | 107 |
| 80 | Successful Long-Term Treatment With Pemetrexed of NSCLC Associated With EML4-ALK and Low Thymidylate Synthase Expression. Clinical Lung Cancer, 2012, 13, 157-159. | 1.1 | 9 |
| 81 | Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab. Science Translational Medicine, 2011, 3, 99ra86. | 5.8 | 543 |
| 82 | SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. International Journal of Cancer, 2009, 124, 1072-1080. | 2.3 | 76 |
| 83 | Establishment and molecular profiling of a novel human pancreatic cancer panel for 5â€FU. Cancer Science, 2008, 99, 1859-1864. | 1.7 | 12 |
| 84 | Dimerization and the signal transduction pathway of a smallinâ€frame deletion in the epidermal growth factor receptor. FASEB Journal, 2006, 20, 311-313. | 0.2 | 41 |
| 85 | Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474. Cancer Research, 2004, 64, 9101-9104. | 0.4 | 112 |
| 86 | Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and CDC2 kinase by paclitaxel. International Journal of Cancer, 1995, 63, 688-693. | 2.3 | 54 |